Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Clin Chem. 2020 Feb 1;66(2):379-389. doi: 10.1093/clinchem/hvz015.
Thrombosis is a major global disease burden with almost 60% of cases related to underlying heredity and most cases still idiopathic. Synonymous single nucleotide polymorphisms (sSNPs) are considered silent and phenotypically neutral. Our previous study revealed a novel synonymous FII c.1824C>T variant as a potential risk factor for pregnancy loss, but it has not yet been associated with thrombotic diseases.
To determine the frequency of the FII c.1824C>T variant we have sequenced patients' DNA. Prothrombin RNA expression was measured by quantitative PCR. Functional analyses included routine hemostasis tests, western blotting and ELISA to determine prothrombin levels in plasma, and global hemostasis assays for thrombin and fibrin generation in carriers of the FII c.1824C>T variant. Scanning electron microscopy was used to examine the structure of fibrin clots.
Frequency of the FII c.1824C>T variant was significantly increased in patients with venous thromboembolism and cerebrovascular insult. Examination in vitro demonstrated increased expression of prothrombin mRNA in FII c.1824T transfected cells. Our ex vivo study of FII c.1824C>T carriers showed that the presence of this variant was associated with hyperprothrombinemia, hypofibrinolysis, and formation of densely packed fibrin clots resistant to fibrinolysis.
Our data indicate that FII c.1824C>T, although a synonymous variant, leads to the development of a prothrombotic phenotype and could represent a new prothrombotic risk factor. As a silent variant, FII c.1824C>T would probably be overlooked during genetic screening, and our results show that it could not be detected in routine laboratory tests.
血栓形成是一种主要的全球性疾病负担,其中近 60%的病例与潜在遗传有关,大多数病例仍然是特发性的。同义单核苷酸多态性(sSNP)被认为是沉默的,表型上是中性的。我们之前的研究表明,一种新的同义 FII c.1824C>T 变体可能是妊娠丢失的潜在风险因素,但尚未与血栓性疾病相关。
为了确定 FII c.1824C>T 变体的频率,我们对患者的 DNA 进行了测序。通过定量 PCR 测量凝血酶原 RNA 的表达。功能分析包括常规止血试验、western blot 和 ELISA 以确定 FII c.1824C>T 变体携带者血浆中的凝血酶原水平,以及用于检测凝血酶和纤维蛋白生成的全局止血试验。扫描电子显微镜用于检查纤维蛋白凝块的结构。
FII c.1824C>T 变体的频率在静脉血栓栓塞和脑血管损伤患者中显著增加。体外研究表明,FII c.1824T 转染细胞中凝血酶原 mRNA 的表达增加。我们对 FII c.1824C>T 携带者的体外研究表明,该变体的存在与高凝血酶原血症、低纤维蛋白溶解和形成密集的纤维蛋白凝块有关,这些凝块对纤维蛋白溶解有抗性。
我们的数据表明,尽管 FII c.1824C>T 是一种同义变体,但它导致了血栓形成表型的发展,可能代表了一种新的血栓形成风险因素。作为一种沉默变体,FII c.1824C>T 在遗传筛查期间可能会被忽视,我们的结果表明,它不能在常规实验室测试中检测到。